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A t the request of the Councils of The Society of Thoracic Surgeons (STS) and The American 
Association for Thoracic Surgery (AATS), the Ad 
Hoc Liaison Committee for Standardizing Defini- 
tions of Prosthetic Heart Valve Morbidity "revis- 
ited" the Guidelines published in September 1988.1-3 
The purpose of the review was to update and clarify 
definitions within the guidelines and to consider 
recommendations made by others. 4' 5 The variety of 
cardiac valvular procedures has expanded since 
1988; therefore, in this document the term operated 
valve indicates prosthetic and bioprosthetic heart 
valves of all types, operated or repaired native valves, 
and allograft and autografl valves. The term operated 
valve includes any cardiac valve altered by a surgeon 
during an operation. 
Much morbidity and mortality is a direct con- 
sequence of the interaction between the patient 
and operated valve(s), although patient variables 
(e.g., age, degree of coronary arterial disease, 
follow-up care) may be more responsible for 
outcomes than an operated valve. However, no set 
of guidelines can identify all possible patient 
factors that may affect morbidity and mortality. 
General agreement regarding the following defi- 
nitions of terms and suggestions for reporting 
data does not preclude more detailed analyses or 
constructive recommendations, and investigators 
are encouraged to identify relevant patient factors 
in addition to factors related to operated valves. 
This article is being published concurrently in The Journal of 
Thoracic and Cardiovascular Surgery, The Annals of Thoracic 
Surgery, and the European Journal of Cardio- Thoracic Surgery. 
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Purpose 
The purpose of these guidelines i  to facilitate the 
analysis and reporting of results of operations on 
diseased cardiac valves. The definitions and recom- 
mendations that follow are guidelines, not standards, 
and are designed to facilitate comparisons between 
the experiences of different surgeons who treat 
different cohorts of patients at different imes with 
different echniques and materials. 
Mortality 
Thirty-day mortality (sometimes termed operative 
mortality) is death within 30 days of operation regard- 
less of the patient's geographic location. Follow-up for 
30-day mortality must be complete. Hospital mortality 
is death within any time interval after operation if the 
patient is not discharged from the hospital. Hospital to 
hospital transfer is not considered ischarge; transfer 
to a nursing home or ehabilitation unit is considered 
hospital discharge unless the patient subsequently dies 
of complications of the operation. 
Definitions of morbidity 
Structural valvular deterioration (SVD). Any 
change in function (a decrease of one New York 
Heart Association functional class or more) of an 
operated valve resulting from an intrinsic abnormal- 
ity of the valve that causes tenosis or regurgitation. 
Structural valvular deterioration includes oper- 
ated valve dysfunction or deterioration exclusive of 
infection or thrombosis as determined by reopera- 
tion, autopsy, or clinical investigation. The term 
structural deterioration refers to changes intrinsic to 
the valve, such as wear, fracture, poppet escape, 
calcification, leaflet ear, stent creep, and suture line 
disruption of components (e.g., leaflets, chordae) of 
an operated valve. 
Nonstructural dysfunction. Any abnormality re- 
sulting in stenosis or regurgitation at the operated 
valve that is not intrinsic to the valve itself. 
708 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 112, Number 3 
Edmunds et aL 709 
Nonstructural dysfunction refers to nonstructural 
problems that result in dysfunction of an operated 
valve exclusive of thrombosis and infection diagnosed 
by reoperation, autopsy, or clinical investigation. 
Examples of nonstructural dysfunction include en- 
trapment by pannus, tissue, or suture, paravalvular 
leak, inappropriate sizing or positioning, residual 
leak or obstruction from valve implantation or re- 
pair, and clinically important hemolytic anemia. 
Sudden or progressive dysfunction or deteriora- 
tion of the operated valve may be structural, non- 
structural, or both as determined by reoperation, 
autopsy, or clinical investigation. 
Valve thrombosis. Any thrombus, in the absence 
of infection, attached to or near an operated valve 
that occludes part of the blood flow path or that 
interferes with function of the valve. 
Valve thrombosis may be documented by opera- 
tion, autopsy, or clinical investigation. 
Embolism. Any embolic event that occurs in the 
absence of infection after the immediate periopera- 
tire period (when anesthesia-induced unconscious- 
ness is completely reversed). 
A neurologic event includes any new, temporary or 
permanent, focal or global neurologic deficit. A tran- 
sient &chemic attack (TIA) is a fully reversible neuro- 
logic event that lasts less than 24 hours. A reversible 
ischemic neurologic deficit (RIND) is a fully reversible 
neurologic deficit that lasts more than 24 hours and 
less than 3 weeks. A stroke or permanent neurologic 
event lasts more than 3 weeks or causes death. Psy- 
chomotor deficits determined by specialized testing are 
not considered neurologic events related to operated 
valves. Patients who do not awaken or who awaken 
after operation with a new stroke are excluded in 
tabulations of valve-related morbidity. 
A peripheral embolic event is an operative, autopsy, 
or clinically documented embolus that produces ymp- 
toms from complete or partial obstruction of a periph- 
eral (noncerebral) artery. Patients who awake with a 
myocardial infarction are excluded. Patients who have 
a myocardial infarction after the perioperative period 
are also excluded unless a coronary arterial embolus is 
shown to be the cause of the infarction by operation, 
autopsy, or clinical investigation. Emboli proven to 
consist of nonthrombotic material (e.g., atherosclero- 
sis, myxoma) are excluded. 
Bleeding event (formerly anticoagulant-related 
hemorrhage). Any episode of major internal or 
external bleeding that causes death, hospitalization, 
or permanent injury (e.g., vision loss) or necessitates 
transfusion. 
The complication bleeding event applies to all 
patients whether or not they are taking anticoagu- 
lants or antiplatelet drugs, since bleeding events can 
occur in patients who are not receiving anticoagu- 
lants. Embolic stroke complicated by bleeding is 
classified as a neurologic event under embolism and 
is not included as a separate bleeding event. 
The warfarin anticoagulant s atus closest to the 
time that the patient has valve thrombosis, embo- 
lism, or a bleeding event should be reported in 
international normalized ratio units. Whether or not 
patients were receiving a platelet inhibitory drug 
(e.g., aspirin, dipyridamole) should also be reported. 
Operated valvular endocarditis. Any infection 
involving an operated valve. 
The diagnosis of operated valvular endocarditis  
based on customary clinical criteria including an 
appropriate combination of positive blood cultures, 
clinical signs, and histologic onfirmation of endo- 
carditis at reoperation or autopsy. Morbidity associ- 
ated with active infection, such as valve thrombosis, 
thrombotic embolus, bleeding event, or paravalvular 
leak, is included under this category and is not in- 
cluded in other categories of morbidity. 
Consequences of morbid events 
Reoperation. Any operation that repairs, alters, 
or replaces a previously operated valve. 
The reasons for reoperation should be reported 
and may include reasons other than valve-related 
morbidity, such as recall, excessive noise, or inciden- 
tal or prophylactic removal. Enzymatic or catheter- 
aided therapy of valve-related morbidity is not con- 
sidered reoperation, but the morbid event that 
prompted the intervention should be reported. 
Valve-related mortality. Death caused by struc- 
tural valvular deterioration, onstructural dysfunction, 
valve thrombosis, embolism, bleeding event, operated 
valvular endocarditis, or death related to reoperation 
of an operated valve. Sudden, unexplained, unex- 
pected deaths of patients with an operated valve are 
included as valve-related mortality. Deaths caused by 
heart failure in patients with advanced myocardial 
disease and satisfactorily functioning cardiac valves are 
not included. Specific causes of valve-related deaths 
should be designated and reported. 
Sudden, unexpected, unexplained death. The 
cause of these deaths is unknown and the relation- 
ship to an operated valve is also unknown. There- 
fore, these deaths hould be reported as a separate 
category of valve-related mortality if the cause can- 
not be determined by clinical data or autopsy. 
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Cardiac death. All deaths resulting from cardiac 
causes. This category includes valve-related deaths 
(including sudden unexplained eaths) and non- 
valve-related cardiac deaths (e.g., congestive heart 
failure, acute myocardial infarction, documented 
fatal arrhythmias). 
Total deaths. All deaths resulting from any cause 
after a valve operation. 
Permanent valve-related impairment. Any per- 
manent neurologic or other functional deficit caused 
by structural valvular deterioration, nonstructural 
dysfunction, valve thrombosis, thrombotic embo- 
lism, bleeding event, operated valvular endocarditis, 
or reoperation. 
Data collection 
Data collection and reporting for all operated 
valves should include valve location (aortic, mitral, 
tricuspid, pulmonary, aortic and mitral, mitral and 
tricuspid) and category of operated valve (i.e., aortic 
pericardial bioprosthesis, fresh aortic allograft, me- 
chanical mitral prosthesis, tricuspid ring annulo- 
plasty). For prosthetic valves, including bioprosthe- 
ses, the manufacturer and model should be reported 
with designation of different models and manufac- 
turers. For allograft and xenograft valves the 
method of preservation should be given. Valve sizes 
for each category of valve, valve model, and valve 
location should be stated. 
Additional pertinent material. In addition each 
report should specify: 
1. The patient population from which the sample 
population was collected. The inclusive dates of 
operation and whether or not the series was consec- 
utive should be stated. Criteria used to select pa- 
tients should be specified and defined, If a subset of 
the sample population is reported, the total number 
of patients who received an operated valve during 
the same time frame should be reported. 
2. The method employed for follow-up (e.g., 
examination, telephone, letter, retrospective r view 
versus prospective study). The percentages of re- 
sponses from each method should be given. 
3. The time period (dosing interval) required to 
complete current follow-up. (The closing interval, in 
which the present status of all patients is deter- 
mined, should be as short as possible.) 
4. The completeness of follow-up during the 
closing interval. (This should be 95% or better.) 
5. The percentage of autopsies and documented 
causes of death. 
6. New York Heart Association functional class at 
the time of follow-up. 
Data analysis and reporting 
The method of reporting data should facilitate 
comparison between reports and support the con- 
clusions, inferences, and predictions made. Some 
methods that may be useful are discussed below. 
The methods chosen to analyze the collected data 
will be influenced by the purpose of the report and 
the availability of various analytical techniques. 
Methods used in the collection and analysis of data 
should be defined in the Methods section by refer- 
ences or defined in an appendix. 
As with cardiac surgery, statistical science is a 
dynamic discipline and the methods used may vary 
between statisticians. However, in all reports the 
conclusions, predictions, and inferences made 
should be supported by the collected data and 
appropriate analysis of the data. 
Percentages (not time-related). Some morbid 
events that occur within a short time frame (such as 
the interval between operation and 30 days or 
hospital discharge) may be reported as a simple 
percentage, that is, the number of events divided by 
the number of patients (e.g., percent operative 
mortality). Percentages should be presented with 
confidence intervals 6 and may be compared by X z 
analysis of Fisher's exact est. 7 Logistic regression s is 
available for evaluating the simultaneous influence 
of several risk factors on a dichotomous outcome 
variable (percentage) and is often used to establish 
a risk model, that is, a mathematical formula that 
incorporates such factors. 
Time-related events. Most valve-related events 
should be reported in a time-related manner, with 
operation designated as time zero. Kaplan-Meier 9 
or other life table techniques 1° provide actuarial 
estimates of morbid events and should be reported 
with the standard error of the estimate or with 
appropriate (usually 67% or 95%) confidence limits. 
The number of patients remaining at risk should be 
indicated at appropriate intervals, and curves hould 
not be extrapolated beyond time frames containing 
very few patients. Although comparisons between 
subsets of patients can be made, actuarial methods 
are not predictive beyond the time of the last 
actuarial estimate and cannot be adapted to multi- 
variate analysis. These methods are called nonpara- 
metric or distribution-free because they do not 
assume aparticular statistical distribution or model. 
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The Cox proportional hazard model 11 produces 
time-dependent analysis of valve-related events and 
provides a multivariable, stepwise regression 
method to identify risk factors associated with spe- 
cific valve-related morbid events during specific time 
intervals. The Cox method is a semiparametric 
(model partly specified) approach, which makes no 
assumption about the shape of the underlying haz- 
ard function, but identifies risk factors and estimates 
multipliers of the baseline hazard that are the 
relative risks associated with the risk factors. Several 
methods are available for assessing the assumption 
of proportional hazards, a2 The results of a multiva- 
riable analysis hould be accompanied by a list of the 
variables considered and a tabular presentation of 
the numerical results. 
A fully parametric method (model completely 
specified) of calculating a hazard function f valve- 
related morbid events defines the instantaneous ri k 
of an event at any time after operationJ 3-16 Such 
methods permit univariate and multivariate analysis, 
provide predictive information beyond the time of 
the last event, indicate whether the risk is constant, 
and provide confidence limits. 
Linearized rates. Some of the aforementioned 
methods have been extended to consider repeated 
events in the same patient, although the software isnot 
widely available. A simple and widely used approach 
uses "linearized" rates (events per 100 patient-years or 
percent per year, calculated as the number of events 
divided by the total patient-years) to summarize the 
incidence of multiple events in individual patients. 
These rates should be considered only approximate 
unless the hazard function for the complication under 
study is constant during the entire time interval con- 
sidered (which is often not true with regard to the early 
postoperative p riod) and unless the risk of recurrent 
events is the same as for initial events (which is often 
not the case). Linearized rates should be reported with 
confidence limits, which can be based on the Poisson 
distribution 17or on likelihood ratio methods for com- 
paring the means of exponential distributions. 11'1s 
Linearized rates can be compared using the likelihood 
ratio test Is' 16,19 or a test based on the F-statistic. 11' 16 
Cumulative incidence. The hazard function for a 
given morbid event represents a potential risk; its 
realization as an actual occurrence is influenced by 
the competing risks of other events, such as death or 
explant, which may terminate the valve's use before 
the event being analyzed can occur. The usual 
actuarial estimates 9' 10 assume that such terminating 
events are eliminated; it may be useful to determine 
the actual probability of occurrence, often called the 
cumulative incidence, which is less than that esti- 
mated by the usual actuarial method. 4 
The Committee thanks all respondents who contributed 
to this document and especially Eugene H. Blackstone, 
MD, who provided particularly valuable criticism and 
information. 
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